Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential
-
By
-
Cuiling Zheng
-
June 5, 2026
-
Clinical Scorecard: The Role of Autoantibodies in Cancer: Implications for Diagnosis, Prognosis, and Treatment
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Tumor-associated autoantibodies (TAAbs) are produced in response to tumor-associated antigens (TAAs). |
| Target Population | |
| Care Setting | |
Key Highlights
- TAAbs can be detected years before clinical symptoms appear.
- They demonstrate stability in serum for up to 3 months.
- Detection methods include ELISA, immunofluorescence, and protein chip technology.
Guideline-Based Recommendations
Diagnosis
- Utilize TAAbs as immunodiagnostic markers for early cancer detection.
Management
- Monitor TAAbs for tracking therapy effectiveness.
Monitoring & Follow-up
- Establish long-term monitoring of patients’ immune repertoires.
Risks
- Consider the potential for increased autoimmune risk due to inflammatory cytokines.
Patient & Prescribing Data
TAAbs may indicate immunotherapy efficacy.
Clinical Best Practices
- Employ minimally invasive methods for TAAbs detection.
Related Resources & Content
